Ameriprise
MXCT icon

Ameriprise’s MaxCyte MXCT Stock Holding History

Ameriprise’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$101K Sell
144,087
-29,886
-17% -$27.9K ﹤0.01% 3958
2025
Q4 		$270K Buy
+173,973
New +$278K ﹤0.01% 3835
2024
Q4 		– Sell
-1,116,300
Closed -$4.34M – 4133
2024
Q3 		$4.34M Sell
1,116,300
-17,075
-2% -$71.9K ﹤0.01% 2471
2024
Q2 		$4.44M Sell
1,133,375
-10,162
-0.9% -$43.7K ﹤0.01% 2392
2024
Q1 		$4.79M Sell
1,143,537
-305,370
-21% -$1.43M ﹤0.01% 2406
2023
Q4 		$6.81M Buy
1,448,907
+139,629
+11% +$544K ﹤0.01% 2106
2023
Q3 		$4.08M Sell
1,309,278
-10,461
-0.8% -$42.1K ﹤0.01% 2441
2023
Q2 		$6.06M Sell
1,319,739
-9,826
-0.7% -$45.2K ﹤0.01% 2193
2023
Q1 		$6.58M Buy
+1,329,565
New +$6.55M ﹤0.01% 2120

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFM
Brooklands Fund Management London, United Kingdom $88.9M AUM

Ameriprise's MXCT Position: Q1 2026 in Review

Ameriprise reduced its MaxCyte (MXCT) stake by 17% in Q1 2026, selling an estimated $27.9K and leaving 144,087 shares worth $101K. The position accounts for ﹤0.01% of the portfolio, ranked #3958.

Ameriprise first reported a position in MXCT in Q1 2023 and has held it in 9 quarters since. The position peaked at $6.81M in Q4 2023. 130 funds tracked by Wall St. Rank hold MXCT as of Q1 2026.

  • Ameriprise held 144,087 shares of MaxCyte worth $101K as of Q1 2026.
  • Ameriprise sold 29,886 MaxCyte shares in Q1 2026, an estimated $27.9K.
  • MaxCyte made up ﹤0.01% of Ameriprise's portfolio in Q1 2026, its #3958 holding.
  • Ameriprise first reported a position in MaxCyte in Q1 2023 and has held it in 9 quarters since.
  • Ameriprise's MaxCyte position peaked at $6.81M in Q4 2023.
  • 130 funds tracked by Wall St. Rank held MaxCyte as of Q1 2026.

Based on Ameriprise's 13F filing for Q1 2026, filed 15 May 2026.